Online first
Research paper
Published online: 2023-10-10

open access

Page views 236
Article views/downloads 140
Get Citation

Connect on Social Media

Connect on Social Media

Non-drug related costs of treatment with pertuzumab and trastuzumab in HER2-positive breast cancer patients in Poland

Michał Seweryn12, Tomasz Banaś3, Joanna Augustyńska2, Agnieszka Leszczyńska2, Paweł M. Potocki4

Abstract

Introduction. HER2-positive breast cancer represents 10–20% of all breast tumors. This study aimed to create a model-based cost-minimization analysis that compared non-drug related costs of different therapies used in the treatment of HER2-positive breast cancer in Poland: pertuzumab SC plus trastuzumab SC (Pert/TrasSC) vs. pertuzumab IV plus trastuzumab IV (PertIV + TrasIV) vs. pertuzumab IV plus trastuzumab SC (PertIV + TrasSC). 

Material and methods. The cost-minimization analysis was based on the results of a questionnaire addressed to leading oncology centers in Poland. The model was broken down into three categories of cost savings: reduced labor costs of nurses, pharmacists and non-drug related consumables, and from two categories of treatment time reduction: occupation of infusion chair and duration of hospital stay. Data on resources used and costs were collected in the first half of 2022. 

Results. Data were obtained from four oncology centers. The savings generated per patient from healthcare personnel’s work and from non-drug consumables for the Pert/TrasSC arm were 178 PLN compared to PertIV + TrasIV and 168 PLN compared to PertIV + TrasSC. Full adaptation of Pert/TrasSC was estimated to result in average 8-fold higher savings in healthcare personnel workload per patient and in a treatment capacity increase of 241 patients. 

Conclusions. Our model shows that Pert/TrasSC treatment is associated with significantly lower labor costs for nurses and pharmacists and lower costs of non-drug consumables compared to the other treatment options. Moreover, it reduced patients’ chair time due to shorter administration/observation time and released capacity in chemotherapy infusion sites.

Article available in PDF format

View PDF Download PDF file

References

  1. European Cancer Information System (ECIS) . https://ecis.jrc.ec.europa.eu/info/initiatives.html (27.08.2020).
  2. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. https://onkologia.org.pl/pl/raporty (10.07.2020).
  3. Seweryn M, Banaś T, Streb J, et al. Discrepancies in breast cancer management. J Health Inequal. 2021; 7(1): 63–69.
  4. EUROSTAT. Preventable and treatable mortality statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Preventable_and_treatable_mortality_statistics#Overview (02.08.2020).
  5. Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021; 59: 339–350.
  6. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(8): 1194–1220.
  7. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623–1649.
  8. PH FDC SC FDA Approval History. https://www.drugs.com/history/phesgo.html (25.08.2022).
  9. Gao JJ, Osgood CL, Gong Y, et al. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021; 27(8): 2126–2129.
  10. Summary of Product Characteristics, Phesgo, INN-pertuzumab/trastuzumab. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf (25.08.2022).
  11. Tan AR, Im SA, Mattar A, et al. FeDeriCa study group. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021; 22(1): 85–97.
  12. Tan AR, Im SA, Mattar A, et al. FeDeriCa study group. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021; 22(1): 85–97.
  13. NCCN Clinical Practice Guidelines in Oncology, Phesgo recommendation. https://www.phesgo-hcp.com/ (25.08.2022).
  14. Jackisch C, Manevy F, Frank S, et al. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example. Adv Ther. 2022; 39(2): 833–844.
  15. O'Shaughnessy J, Sousa S, Cruz J, et al. PHranceSCa study group. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021; 152: 223–232.
  16. Bellone M, Pradelli L, Sanfilippo A, et al. POSC113 Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer (HER2+ BC) Patients in Italy: A Budget Impact Analysis. Value in Health. 2022; 25(1): S109.
  17. Manevy F, Filkauskas G, Levy P, et al. Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States. J Clin Oncol. 2021; 39(15_suppl): 544–544.
  18. Dang C, Tolaney S, Riaz F, et al. Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. J Clin Oncol. 2022; 40(16_suppl): 1515–1515.
  19. Radecka B, Hudała-Klecha J, Sawka D, et al. Home-based treatment with subcutaneous trastuzumab: safe and acceptable not only during a pandemic — final analysis of the RWD project ‘FlexCare’. Oncol Clin Pract. 2023.
  20. OECD Health et Glance 2021 report. https://www.oecd.org/health/health-at-a-glance/ (25.08.2022).